MarketPeel
Insider Trading Intelligence
Pricing
…
MM

Masaru Matsuda

ARQT
SEE REMARKS · ARCUTIS BIOTHERAPEUTICS, INC. · CIK 0001798679
FILING MIX · LIFETIME41%/59%
BUYS
32
SELLS
46
TOTAL VALUE
$3.61M
COMPANIES
2
ACTIVE SINCE
Feb 2020
HOLDINGS NOW
146,738
AVG SELL PX
$20.22
TRADE KIND
SHOWING 78 / 78
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
33 backtested trades · 8 horizons · 54 pending
Forward-return performance of every backtestable P/S trade by Masaru Matsuda, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d33+42.42%+1.00%+0.38%+0.62%+1.42%0.35
14d33+45.45%+0.89%+0.32%+0.57%+1.36%0.24
30d33+51.52%+4.74%+0.36%+5.24%+1.87%1.66
60d33+51.52%+8.56%+2.14%+6.42%-0.35%1.60
90d33(2 pending)+54.84%+17.54%+4.12%+18.30%+1.50%—
180d33(10 pending)+52.17%+28.41%+8.96%+22.08%+7.04%—
1y33(17 pending)+25.00%+79.33%+18.28%+62.64%+40.58%—
2y33(25 pending)+37.50%+216.54%+44.30%+183.49%+28.72%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
ARQT · 126,689 shares · as of May 4, 2026
053,173106,346159,519212,6922023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 32 buys / 46 sellsCOVERAGE · 26 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
7,372$23.27$171.5K127,573May 4, 2026May 6, 2026 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
884$23.61$20.9K126,689May 4, 2026May 6, 2026 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
6,553$25.16$164.9K137,125Mar 2, 2026Mar 3, 2026 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
1,987$25.70$51.1K136,932Mar 2, 2026Mar 3, 2026 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
193$25.91$5.0K136,932Mar 2, 2026Mar 3, 2026 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
97,000——97,000Feb 27, 2026Mar 3, 2026 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
37,000——147,003Feb 27, 2026Mar 3, 2026 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
3,325$27.95$92.9K143,678Feb 27, 2026Mar 3, 2026 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
8,562$24.97$213.8K134,096Feb 2, 2026Feb 4, 2026 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
4,714$25.63$120.8K110,003Feb 2, 2026Feb 4, 2026 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
7,983$25.50$203.6K142,658Feb 2, 2026Feb 4, 2026 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
19,379$25.24$489.1K114,717Feb 2, 2026Feb 4, 2026 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
1,657$30.23$50.1K150,641Dec 1, 2025Dec 3, 2025 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
1,561$28.50$44.5K151,476Nov 19, 2025Nov 21, 2025 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
989$27.95$27.6K153,037Nov 19, 2025Nov 21, 2025 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
43$25.40$1.1K154,026Nov 3, 2025Nov 5, 2025 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
7,165$24.71$177.1K154,069Nov 3, 2025Nov 5, 2025 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
36,130$16.16$583.7K161,234Sep 4, 2025Sep 8, 2025 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
6,330$14.33$90.7K197,364Aug 4, 2025Aug 5, 2025 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
1,800$13.78$24.8K202,599May 28, 2025May 29, 2025 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
5,030$15.20$76.5K204,399May 2, 2025May 5, 2025 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
3,263$13.03$42.5K209,429Mar 3, 2025Mar 4, 2025 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
34,000——212,692Feb 28, 2025Mar 4, 2025 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
89,000——89,000Feb 28, 2025Mar 4, 2025 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
8,338$12.70$105.9K178,692Feb 3, 2025Feb 4, 2025 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASE
See Remarks
1,657$7.11$11.8K187,030Nov 30, 2024Dec 3, 2024 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
1,775$9.68$17.2K181,373Nov 19, 2024Nov 19, 2024 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
4,875——183,148Nov 18, 2024Nov 19, 2024 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
5,015$8.68$43.6K178,273Nov 4, 2024Nov 5, 2024 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
5,220$9.02$47.1K183,288Aug 2, 2024Aug 5, 2024 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASE
See Remarks
4,000$1.69$6.8K185,373May 31, 2024Dec 3, 2024 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
1,775$9.01$16.0K188,508May 28, 2024May 29, 2024 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
4,875——190,283May 27, 2024May 29, 2024 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
5,016$8.74$43.8K185,408May 2, 2024May 3, 2024 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
3,760$11.12$41.8K190,424Mar 4, 2024Mar 6, 2024 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE
See Remark
185,000——0Feb 13, 2024Feb 15, 2024 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
17,650——166,284Feb 13, 2024Feb 15, 2024 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE
See Remark
55,800——0Feb 13, 2024Feb 15, 2024 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
27,900——194,184Feb 13, 2024Feb 15, 2024 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE
See Remark
35,300——0Feb 13, 2024Feb 15, 2024 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
74,000——148,634Feb 13, 2024Feb 15, 2024 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
176,000——176,000Jan 12, 2024Jan 17, 2024 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
28,000——74,634Jan 12, 2024Jan 17, 2024 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE
See Remark
1,850$1.98$3.7K46,634Nov 21, 2023Nov 21, 2023 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
4,875——48,484Nov 18, 2023Nov 21, 2023 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
1,463$6.38$9.3K43,609May 31, 2023Jun 2, 2023 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE
See Remark
1,830$7.80$14.3K42,146May 31, 2023Jun 2, 2023 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
4,875——43,976May 27, 2023Jun 2, 2023 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE
See Remarks
18$16.52$29718,101Mar 2, 2023Mar 6, 2023 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
21,000——39,101Mar 2, 2023Mar 6, 2023 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
55,800——55,800Mar 2, 2023Mar 6, 2023 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE
See Remarks
1,416$15.82$22.4K18,119Mar 2, 2023Mar 6, 2023 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE
See Remark
1,720$18.19$31.3K19,535Nov 21, 2022Nov 22, 2022 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
4,875——21,255Nov 18, 2022Nov 22, 2022 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
SALE
SVP and General Counsel
1,795$19.73$35.4K16,380Jun 2, 2022Jun 2, 2022 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
4,875——18,175May 27, 2022Jun 2, 2022 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
35,300——35,300Mar 3, 2022Mar 7, 2022 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
13,300——13,300Mar 3, 2022Mar 7, 2022 ↗View →
ARQT
ARCUTIS BIOTHERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
185,000——185,000Jan 3, 2022Jan 5, 2022 ↗View →
HALO
HALOZYME THERAPEUTICS, INC.
PURCHASE
SVP, General Counsel
6,883——23,461Sep 4, 2021Sep 7, 2021 ↗View →
HALO
HALOZYME THERAPEUTICS, INC.
SALE
SVP, General Counsel
6,883——6,883Sep 4, 2021Sep 7, 2021 ↗View →
HALO
HALOZYME THERAPEUTICS, INC.
SALE
SVP, General Counsel
3,412$42.22$144.1K20,049Sep 4, 2021Sep 7, 2021 ↗View →
HALO
HALOZYME THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
23,311——23,311Feb 15, 2021Feb 17, 2021 ↗View →
HALO
HALOZYME THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
13,544——13,544Feb 15, 2021Feb 17, 2021 ↗View →
HALO
HALOZYME THERAPEUTICS, INC.
PURCHASE
SVP, General Counsel
4,129——18,625Feb 12, 2021Feb 12, 2021 ↗View →
HALO
HALOZYME THERAPEUTICS, INC.
SALE
SVP, General Counsel
2,047$49.84$102.0K16,578Feb 12, 2021Feb 12, 2021 ↗View →
HALO
HALOZYME THERAPEUTICS, INC.
SALE
SVP, General Counsel
4,129——8,258Feb 12, 2021Feb 12, 2021 ↗View →
HALO
HALOZYME THERAPEUTICS, INC.
PURCHASE
SVP, General Counsel
6,257——17,699Feb 10, 2021Feb 12, 2021 ↗View →
HALO
HALOZYME THERAPEUTICS, INC.
SALE
SVP, General Counsel
3,203$50.60$162.1K14,496Feb 10, 2021Feb 12, 2021 ↗View →
HALO
HALOZYME THERAPEUTICS, INC.
SALE
SVP, General Counsel
6,257——18,769Feb 10, 2021Feb 12, 2021 ↗View →
HALO
HALOZYME THERAPEUTICS, INC.
SALE
SVP, General Counsel
6,884——13,766Sep 4, 2020Sep 4, 2020 ↗View →
HALO
HALOZYME THERAPEUTICS, INC.
SALE
SVP, General Counsel
2,380$27.70$65.9K11,442Sep 4, 2020Sep 4, 2020 ↗View →
HALO
HALOZYME THERAPEUTICS, INC.
PURCHASE
SVP, General Counsel
6,884——13,822Sep 4, 2020Sep 4, 2020 ↗View →
HALO
HALOZYME THERAPEUTICS, INC.
SALE
SVP, General Counsel
1,681$20.00$33.6K6,938Feb 12, 2020Feb 13, 2020 ↗View →
HALO
HALOZYME THERAPEUTICS, INC.
PURCHASE
SVP, General Counsel
4,130——8,619Feb 12, 2020Feb 13, 2020 ↗View →
HALO
HALOZYME THERAPEUTICS, INC.
SALE
SVP, General Counsel
4,130——12,387Feb 12, 2020Feb 13, 2020 ↗View →
HALO
HALOZYME THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
25,026——25,026Feb 10, 2020Feb 12, 2020 ↗View →
HALO
HALOZYME THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
53,211——53,211Feb 10, 2020Feb 12, 2020 ↗View →
Other insiders · ARQT
Loading peer insiders…
About this filer
CIK 0001798679
ROLE
See Remarks
PRIMARY
ARQT
COMPANIES
2
ACTIVE SINCE
Feb 2020
MARKETPEEL · /INSIDER/0001798679DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback